Pfizer’s Hympavzi Approved for Treatment of Certain Types of Hemophilia
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
FiercePharma14h
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
Managed Healthcare Executive12h
FDA Approves Hympavzi for Hemophilia A and B
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
hemophilianewstoday14h
FDA approves marstacimab, now Hympavzi, for hemophilia
The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...
FDA approves first once-weekly drug treatment regimen for hemophilia
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
Daily7h
FDA Approves New new treatment option for cutting bleeding in Hemophilia A or B
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ...
US FDA approves Pfizer's drug for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...
USFDA approves Pfizer's Hympavzi for rare bleeding disorder hemophilia
The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia ...
Medscape13h
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
Business Insider5h
FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents
(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of ...
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ ...